Multiclinic Double‐Blind Comparison of Triazolam and Flurazepam for Seven Nights in Outpatients with Insomnia

Publisher Website
Google Scholar
Abstract
In a 2-clinic 7 day double-blind study, 0.5 mg triazolam (Halcion) was compared to flurazepam (Dalmane) in treatment of insomnia. Two clinical investigators completed 118 outpatients, 61 on triazolam and 57 on flurazepam. Five patients, 4 on triazolam and 1 on flurazepam, discontinued because of side effects; and 3 patients, 1 on triazolam and 2 on flurazepam, discontinued because of ineffectiveness of the medication. Analysis of pooled data for 110 evaluable patients showed that 0.5 mg triazolam was significantly better than 30 mg flurazepam on parameters of how much the medication helped patients sleep, onset of sleep, duration of sleep, evaluation of duration of sleep and feeling of restfulness in the morning. The trend for all other parameters favored triazolam treatment, but values did not reach statistical significance. Side effects were similar in both groups; drowsiness was reported most frequently. No change in efficacy indicating tolerance development during the 7 days of drug administration was observed in either group.

This publication has 7 references indexed in Scilit: